Slide 1: Investor Presentation August 2022
INVESTOR PRESENTATION OTCPink: BNKL August 2022
Slide 2: Forward Looking Statements
OTCPink: BNKL Forward Looking Statements This document is private and confidential, and contains sensitive business information of BIONIK Laboratories Corp. (“BIONIK”) and is not for public distribution. This document has been prepared for informational purposes only and is provided personally to yo
Slide 3: Company Overview
Investor presentation Company Overview BIONIK Laboratories (OTCPink: BNKL) is a global pioneering healthcare company working to transform neurorehabilitation by helping millions reclaim their mobility through cloud - connected, robotic evaluation and therapy. BIONIK’s suite of robotic rehabilitation
Slide 4: Investment Highlights
Investor presentation Investment Highlights Gold standard for robotic upper extremity rehabilitation Expanding distribution to new international markets including the EU, China, Canada & Brazil Expanding portfolio of products and AI capabilities to increase connectivity, productivity and patient car
Slide 5: Market Opportunity
Investor presentation Market Opportunity BIONIK is targeting a growing global market for recovery and rehabilitation: 5 The global market for rehabilitation devices is projected to reach $16.6 billion in 2025 The rehabilitation robotics market is forecast to be valued at $2.6 billion by 2026 The glo
Slide 6: Stroke by Numbers
Investor presentation Stroke by Numbers 6 Someone in the United States has a stroke every 40 seconds Worldwide, 15 million people suffer a stroke each year Up to 30% of stroke survivors are left permanently disabled, requiring specialized treatment for rehabilitation Heart disease and stroke cost th
Slide 7: Overview
Investor presentation Overview 7 BIONIK InMotion systems are the gold standard for robotic upper extremity rehabilitation as supported by 200 peer reviewed clinical studies. 450 BIONIK devices now installed in 20 countries worldwide, with more than 300 of these in the United States. A collaboration
Slide 8: The BIONIK Solution
Investor presentation The BIONIK Solution 8 BIONIK's devices deliver compelling economic benefits with a ~25% reduction in healthcare costs following InMotion therapy. The company's robotic devices provide hope and motivation for patients and their families as they work through recovery. BIONIK Robo
Slide 9: InMotion Therapy is the Established Standard of Care for Upper Extremity Neuro Rehab
Investor presentation InMotion Therapy is the Established Standard of Care for Upper Extremity Neuro Rehab 9 • Supported by more than 200 independent, peer - reviewed articles beginning with ground - breaking MIT research. 1 • Significant improvements in chronic stroke 2 • Improvements seen 3 years
Slide 10: Focus on Clinical Results
Investor presentation Focus on Clinical Results 10
Slide 11: Product Portfolio
Investor presentation Product Portfolio BIONIK’s product portfolio includes two robotic devices and one cloud - based data software solution 11 Provides safe and effective sensorimotor therapy to patients with real - time "assistance - as - needed” Clinicians can customize therapy to the specific ne
Slide 12: Competitive Advantages
Investor presentation Competitive Advantages BIONIK's robotic devices and InMotion cloud - based software solution offer evidence - based therapy intervention, making rehabilitation methods and processes smarter and more intuitive, and potentially facilitating faster patient recovery. 12 Suite of pr
Slide 13: Price Competitive Matrix
Investor presentation Feature InMotion ARM/HAND Power Spring ReoGo Diego/Amadeo Burt AI Data Collection AI Patient Assistance Cloud Connectivity Research Driven Evaluation Capabilities Hand System * Price Competitive Matrix 13 *Requires purchase of separate system (Amadeo)
Slide 14: Growth Strategy
Investor presentation Growth Strategy 14 DATA ENHANCEMENT • IMC - Data to Patient • New SaaS Products CENTERS OF EXCELLENCE • Neuro - recovery Care Continuum • BIONIK Technology COMMERCIAL • Expansion of InMotion Tech to New Markets • EU, China, Canada & Brazil NEW TECHNOLOGY AND PRODUCTS • M & A •
Slide 15: Centers of Excellence Neuro-recovery Care Centers
Investor presentation Centers of Excellence 15 Neuro - recovery Care Centers Showcase for BIONIK technology and solutions which will act as a vehicle for data strategy and bringing data directly to patients Goal is to expand the continuum of care beyond the boundaries of insurance through robotics T
Slide 16: InMotion Connect: Data is Just the Tip of the Iceberg
Investor presentation InMotion Connect TM Data is Just the Tip of the Iceberg BIONIK - Products & Technology 2.6 16 InMotion Connect TM : Today • Tracking of patient usage • Tracking number of repetitions • Static evaluations • Anonymized data InMotion Connect TM : Tomorrow • Detailed real - time tr
Slide 17: Decision Methodology for Market Expansion
Investor presentation 4.7 ๏ Each market segment / geography is evaluated based on key market variables (size, regulatory and reimbursement, appetite for advanced technologies, effectiveness of local 3 rd party distribution and existing base . ๏ Current Market Priorities » Strategic accounts developm
Slide 18: Pathway to Success
Investor presentation Pathway to Success BIONIK is positioning for growth in the near, medium and long term: 18 Expansion of sales team throughout the world via distributor partnerships and entry into new markets Developing a joint - venture in China to address the Chinese market Planning to launch
Slide 19: Impacting Insurance Reimbursement Now and in the Future
Investor presentation Impacting Insurance Reimbursement Now and in the Future InMotion Eval – objective data used to extend coverage period Private Insurances and CMS moving towards Valued Based Care Model • Medicare payments based on the quality of care provided, rather than on the quantity of serv
Slide 20: Board and Management
Investor presentation 20 André Jacques Auberton - Hervé Chairman of the Board Rémi Gaston Dreyfus Independent Director Peter Gerald Malone Independent Director Audrey D. Thévenon Independent Director Joseph Martin Independent Director Charles Martine Independent Director Michal Prywata Co - Founder
Slide 21: Financial Highlights
Investor presentation Financial Highlights 21 3 Months Ended 6/30/2022 3 Months Ended 6/30/2021 Year Ended 3/31/2022 Year Ended 3/31/2021 Revenue, Net $242,829 $671,283 $1,273,712 $1,193,430 Gross Profit 167,648 540,777 953,258 923,798 Gross Profit Margin % 69.0% 80.6% 74.8% 77.4% Total Non - GAAP O
Slide 22: Key Takeaways
Investor presentation Key Takeaways 22 Gold standard for robotic upper extremity rehabilitation Expanding distribution to new international markets including the EU, China, Canada & Brazil Expanding portfolio of products and AI capabilities to increase connectivity, productivity and patient care out
Slide 23: Global Headquarters
Global Headquarters 80 Coolidge Hill Road Watertown, MA 02472 United States Tel: +1 617.926.4800 support@bioniklabs.com OTCPink: BNKL